AUX-001

About Auxilius Pharma

Auxilius Pharma is a private, pre-revenue biotech targeting high unmet needs in chronic stable angina through its lead program, AUX-001, a once-daily formulation of nicorandil. The company's strategy centers on the 'Value-Added Medicines' paradigm, optimizing established drugs with proven safety and efficacy to create new formulations with improved convenience and clinical benefits, such as reduced hospitalizations. Led by CEO Jed Litwiniuk and supported by a seasoned team and scientific advisory board, Auxilius is positioning its lead candidate as a potential first-line treatment with a unique value proposition for payors due to its risk-reduction profile. The company is currently in Phase 1 development for its sole disclosed asset.

Therapeutic Areas

Other Chronic Stable Angina Drugs